Evidence map›Paper›PMID 30258454›Full record

ReviewFrontiers in plant science2018

A New Zealand Perspective on the Application and Regulation of Gene Editing.

Steffi Fritsche, Charleson Poovaiah, Elspeth MacRae, Glenn Thorlby

Abstract readReview
In one paragraph

Review in Frontiers in plant science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. 3Bs of CRISPR-Cas mediated genome editing in plants: exploring the basics, bioinformatics and biosafety landscape.Physiology and molecular biology of plants : an international journal of functional plant biology · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. An Outlook on Global Regulatory Landscape for Genome-Edited Crops.International journal of molecular sciences · 2021
    Review
  13. Article
  14. Review
  15. Article
  16. Impacts of the regulatory environment for gene editing on delivering beneficial products.In vitro cellular & developmental biology. Plant : journal of the Tissue Culture Association · 2021
    Article
  17. Article
  18. Review
  19. Review
  20. Will cytokinins underpin the second 'Green Revolution'?Journal of experimental botany · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Steffi FritscheScion, Rotorua, New Zealand.
Charleson PoovaiahScion, Rotorua, New Zealand.
Elspeth MacRaeScion, Rotorua, New Zealand.
Glenn ThorlbyScion, Rotorua, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New Zealand (NZ) is a small country with an export-led economy with above 90% of primary production exported. Plant-based primary commodities derived from the pastoral, horticultural and forestry sectors account for around half of the export earnings. Productivity is characterized by a history of innovation and the early adoption of advanced technologies. Gene editing has the potential to revolutionize breeding programmes, particularly in NZ. Here, perennials such as tree crops and forestry species are key components of the primary production value chain but are challenging for conventional breeding and only recently domesticated. Uncertainty over the global regulatory status of gene editing products is a barrier to invest in and apply editing techniques in plant breeding. NZs major trading partners including Europe, Asia and Australia are currently evaluating the regulatory status of these technologies and have not made definitive decisions. NZ is one of the few countries where the regulatory status of gene editing has been clarified. In 2014, the NZ Environmental Protection Authority ruled that plants produced via gene editing methods, where no foreign DNA remained in the edited plant, would not be regulated as GMOs. However, following a challenge in the High Court, this decision was overturned such that NZ currently controls all products of gene editing as GMOs. Here, we illustrate the potential benefits of integrating gene editing into plant breeding programmes using targets and traits with application in NZ. The regulatory process which led to gene editing's current GMO classification in NZ is described and the importance of globally harmonized regulations, particularly to small export-driven nations is discussed.

Indexed as

gene editingindustryNew Zealandregulationtraits

Identifiers

PMID30258454
PMCPMC6144285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.